| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8629185 | ABBVIE | 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-N-ethyl-hept-5-enamide (bimatoprost) in crystalline form II, methods for preparation, and methods for use thereof |
Jul, 2031
(7 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7033605 | ABBVIE | Methods for reducing or preventing transplant rejection in the eye and intraocular implants for use therefor |
Oct, 2020
(3 years ago) | |
| US10398707 | ABBVIE | Hypotensive lipid-containing biodegradable intraocular implants and related implants |
Apr, 2024
(2 days from now) | |
| US8673341 | ABBVIE | Intraocular pressure reduction with intracameral bimatoprost implants |
Feb, 2025
(9 months from now) | |
| US9149428 | ABBVIE | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(2 years from now) | |
| US10441543 | ABBVIE | Processes for making cyclic lipid implants for intraocular use |
Dec, 2026
(2 years from now) | |
| US8206737 | ABBVIE | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2027
(2 years from now) | |
| US7799336 | ABBVIE | Hypotensive lipid-containing biodegradable intraocular implants and related methods |
Apr, 2029
(4 years from now) | |
| US9980974 | ABBVIE | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(10 years from now) | |
| US9492316 | ABBVIE | Prostamide-containing intraocular implants and methods of use thereof |
Oct, 2034
(10 years from now) | |
Durysta is owned by Abbvie.
Durysta contains Bimatoprost.
Durysta has a total of 10 drug patents out of which 1 drug patent has expired.
Expired drug patents of Durysta are:
- US7033605
Durysta was authorised for market use on 04 March, 2020.
Durysta is available in implant;ophthalmic dosage forms.
Durysta can be used as reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant.
The generics of Durysta are possible to be released after 31 October, 2034.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Product(NP) | Mar 04, 2023 |
Drugs and Companies using BIMATOPROST ingredient
Market Authorisation Date: 04 March, 2020
Treatment: Reduction of intraocular pressure (iop) in patients with open angle glaucoma(oag) or ocular hypertension (oht) with a biodegradable bimatoprost implant
Dosage: IMPLANT;OPHTHALMIC
DURYSTA family patents
